The International Journal of Neuropsychopharmacology
August 1, 2025
Giovanni Martinotti, Clara Cavallotto, Giacomo D’andrea et al.
Abstract Background Among the innovative treatments investigated for depression, psilocybin appears to play an extremely promising role, with several studies showing remission rates up to 70% in patients with treatment-resistant depression (TRD) treated with protocols involving a single or double dose administration [1,2]. Psilocybin is a psychedelic compound belonging to the tryptamine class,...
The International Journal of Neuropsychopharmacology
August 1, 2025
Valeria Bruno, Bruce Richardson, Martha López-canul et al.
Abstract Background Recent years have seen renewed scientific interest in psychedelics, including psilocybin, for their potential in treating neuropsychiatric disorders. However, the reward-related properties and behavioral impacts of a high dose of psilocybin remain insufficiently explored. Aims & Objectives Assessing the potential rewarding properties of a high dose of psilocybin (10 mg/kg...
The International Journal of Neuropsychopharmacology
August 1, 2025
Nicolo Fabila, Nimshitha Pavathuparambil Abdul Manaph, V Rudkowsky et al.
Abstract Background Binge eating disorder (BED) is the most prevalent eating disorder, often associated with metabolic syndrome and other mental health comorbidities. Despite its impact, current treatment options remain limited. BED is associated with compulsive intake of foods typically high in fat and sugar, as well as neuroplastic changes in brain regions such as the nucleus accumbens,...
The International Journal of Neuropsychopharmacology
August 1, 2025
B. D. Richardson, Marco Pileggi, Thomas Prudhomme et al.
Abstract Background Psychedelics hold potential as therapeutics in psychological disorders. Even if they primarily act on 5-HT2A receptors, their mechanisms and effects on the brain are not well understood. Simply activating 5-HT2A receptors does not induce psychedelic effects. For example, psilocybin and lisuride both bind to 5-HT2A receptors, but only psilocybin induces hallucinogenic...
International Journal of Drug Policy
August 1, 2025
Karla Hitchins, James P. Reynolds
1 citation
BACKGROUND: Preliminary evidence suggests psilocybin may have therapeutic value for various mental health conditions; despite this, it is currently illegal in the UK. Less is known about how people form their attitudes towards psilocybin policies. OBJECTIVES: To explore whether beliefs about the benefits and safety of psilocybin influence support for psilocybin policies. METHODS: In an online...
The International Journal of Neuropsychopharmacology
August 1, 2025
Susan Meikle, Olivia Carter, Paul Liknaitzky et al.
Abstract Background Depressive disorders are a major global health challenge, with many individuals unresponsive to existing treatments or left with residual symptoms such as impairments in cognition and social functioning. Emerging psychedelic therapies show promise for treating depression but require further research. Aims & Objectives This pilot study aimed to evaluate the feasibility,...
The International Journal of Neuropsychopharmacology
August 1, 2025
Thibault Renoir, James J Gattuso, Bilgenur Bezcioglu et al.
Abstract Background The evident limitations of current treatments for depression, anxiety and obsessive-compulsive disorder (OCD), underscore the need for a paradigm shift in how we understand and treat these disorders. There is enormous public and research enthusiasm for the potential that psychedelic drugs like psilocybin, the psychoactive compound produced by “magic mushrooms” will drive a...
The International Journal of Neuropsychopharmacology
August 1, 2025
C Foldi
Abstract Background Psilocybin, the psychoactive compound produced by so-called “magic” mushrooms has shown promise in alleviating symptoms of a range of psychiatric conditions including depression, anxiety and substance use disorder. Recently, a small Phase 1 trial showed psilocybin to be safe and tolerable for individuals with anorexia nervosa (AN), with 4/10 participants experiencing...
Neuroscience & Biobehavioral Reviews
August 1, 2025
Lucie Berkovitch, Baptiste Fauvel, Katrin H. Preller et al.
8 citations
Psilocybin is a psychedelic serotonergic compound that is renowned for its potent psychoactive effects. Over the past 15 years, an increasing number of controlled clinical trials showed that it has a fast-acting and sustainable efficacy in treating various psychiatric disorders. Neuroimaging studies have been conducted with the objective of elucidating the neurobiological mechanisms underlying...
bioRxiv (Cold Spring Harbor Laboratory)
July 31, 2025
Rick Zirkel, Matthew Isaacson, Clara Liao et al.
3 citations
preprint
Abstract Psilocybin has profound therapeutic potential for various mental health disorders, but its mechanisms of action are unknown. Functional MRI studies have reported the effects of psilocybin on brain activity and connectivity; however, these measurements rely on neurovascular coupling to infer neural activity changes and assume that blood flow responses to neural activity are not altered...